Chest
Special FeatureSpecial Considerations for Patients With Cystic Fibrosis Undergoing Lung Transplantation
Section snippets
Timing of Lung Transplantation
Several studies456789 from the past few years have attempted to assess the risk of death in cohorts of CF patients based on several baseline characteristics. According to these studies, several factors, in addition to FEV1, have been shown as important predictors. According to the largest studies,4 using data from the Cystic Fibrosis Registry, pulmonary function, number of exacerbations, age, gender, weight, presence of diabetes, pancreatic insufficiency, and type of bacterial colonization are
Bacterial Colonization/Infection
The majority of CF patients are colonized/infected with Pseudomonas aeruginosa by the time they are considered for lung transplantation. In most cases, there are mucoid and nonmucoid strains of the organism in the lungs of the transplant recipient.16 The impact of the resistance pattern of the Pseudomonas strains before lung transplantation appears to be minimal on survival after lung transplantation. Three smaller studies171819 have provided conflicting results, while a larger study20 has
Colonization/Infection With Fungi and Mycobacteria
There is less information available on the significance of colonization/infection with fungi prior to lung transplantation. Aspergillus species are isolated before transplantation in 10 to 25% of patients with CF.1525 Their presence does not appear to predict the isolation of fungal species after transplantation and it does not predict outcome.2627 Aspergillus is frequently isolated in patients with anastomotic problems after transplantation, whether they have CF or not.28
A rarer form of
Diabetes Mellitus
The prevalence of diabetes mellitus in patients with CF has been increasing, since more patients are living longer.34 This is a problem for pancreatic-insufficient patients, who comprise 85 to 90% of patients with CF. In a recent study,35 approximately 30% of adult patients undergoing lung transplantation had CF-related diabetes. In addition, diabetes develops in approximately 20% of patients posttransplant, usually in the early postoperative period.35
The presence of diabetes has been
GI and Hepatic Issues
CF patients with pancreatic insufficiency require enzyme supplementation in order to absorb nutrients. There is no compelling evidence, but most experts have suggested that pancreatic enzymes should be given along with immunosuppressive medications in order to improve absorption.36 Therapy with pancreatic enzymes should be started as soon as possible after the transplant operation. It can be more difficult to achieve therapeutic levels for CF patients with either cyclosporine A or tacrolimus.37
Sinusitis
Sinusitis is very common in patients with CF. They are frequently colonized/infected with organisms similar to those in their lungs. Fear of spreading the infection to the new lungs in the setting of immunosuppression has prompted many centers to attempt preemptive operations and drainage of the sinuses.44 However, outcomes did not change, and at this time routine surgical drainage of the sinuses prior to lung transplantation cannot be recommended. A more recent study45 has suggested that
Nutrition
Malnutrition is an independent predictor of poor outcomes in CF patients. Studies4647 have shown that poor nutritional status leads to worse outcomes after lung transplantation and while the patient is on the transplant waiting list. Efforts to improve nutrition by using supplementation via nasogastric/nasojejunal or with percutaneous gastrostomy/jejunostomy tube insertion are usually undertaken. No absolute level of malnutrition precludes patients from undergoing lung transplantation, but
Other Issues
Osteoporosis is common in patients with end-stage lung disease.49 CF patients are particularly vulnerable to osteoporosis because of vitamin D absorption issues, in addition to chronic lung disease. Osteoporosis tends to worsen after lung transplantation because of steroid and calcineurin inhibitor use.50 Aggressive calcium and vitamin D supplementation with concomitant use of bisphosphonates can lead to maintenance of or improvement in bone density.51 Severe, symptomatic osteoporosis is a
Living Donor Lung Transplantation
The shortage of donor organs and the previous UNOS lung allocation system (which gave priority to patients based on time spent on the waiting list) led to a significant number of deaths of patients who were on the list.2 Living-donor lung transplantation was undertaken for selected patients in order to circumvent the above situation. In that operation, two lower lobes are obtained from taller healthy donors and are placed in the chest cavity of a smaller recipient.53
The operation has been
Complications of Lung Transplantation
There are several transplant-specific complications that occur in transplant recipients, irrespective of pretransplant diagnosis. These will only be mentioned briefly in the article, and the list is not inclusive. CF patients are at risk, like all other transplant recipients; however, they need to be counseled about the possibility of these complications.
In the early postoperative period, primary graft dysfunction occurs in approximately 10% of patients, with patients presenting with multilobar
Expected Outcomes
CF patients achieve normal lung function after lung transplantation.60 The improvement continues in the first posttransplant year, but lung function declines as chronic rejection starts to occur. In addition, normalization of the blood gases is expected early after transplantation, usually before hospital discharge.
Exercise tolerance significantly improves after lung transplantation. CF patients achieve improvement in their New York Heart Association (NYHA) class and their 6-min walk distances
Conclusions
Lung transplantation occurs in an increasing number of CF patients. There are several issues unique to this population requiring special attention and management. However, as a group their outcomes are somewhat better than those of non-CF patients. Progress has been made in understanding the factors that affect outcomes before and after transplantation. Nevertheless, there are several areas where improved understanding of the mechanisms that lead to complications after transplantation could
References (61)
- et al.
Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult lung and heart-lung transplant report; 2005
J Heart Lung Transplant
(2005) - et al.
Thoracic organ transplantation in the United States, 1995ā2004
Am J Transplant
(2006) - et al.
Lung function decline in cystic fibrosis patients and timing for lung transplantation referral
Chest
(2004) - et al.
Development of the new lung allocation system in the United States
Am J Transplant
(2006) - et al.
Effect of lung allocation score on waiting list rankings and transplant procedures
J Heart Lung Transplant
(2006) - et al.
The impact of pan-resistant bacterial pathogens on survival after lung transplantation in cystic fibrosis: results from a single large referral centre
J Hosp Infect
(2004) - et al.
Pulmonary transplantation for cystic fibrosis: pre-transplant recipient characteristics in patients dying of peri-operative sepsis
J Heart Lung Transplant
(2003) - et al.
Clinical outcome of Burkholderia cepacia complex infection in cystic fibrosis adults
J Cyst Fibros
(2004) - et al.
Infections in patients with cystic fibrosis following lung transplantation
Chest
(1997) - et al.
Pulmonary aspergillosis in cystic fibrosis lung transplant recipients
Chest
(1998)
Outcome of lung transplantation in patients with mycetomas
Chest
Clinical importance of cystic fibrosis-related diabetes
J Cyst Fibros
Tacrolimus pharmacokinetics and dose monitoring after lung transplantation for cystic fibrosis and other conditions
Am J Transplant
GI complications after lung transplantation in patients with cystic fibrosis
Chest
Epidemiology of liver disease in cystic fibrosis: a longitudinal study
J Hepatol
Nutritional assessment of the lung transplant patient: body mass index as a predictor of 90-day mortality following transplantation
J Heart Lung Transplant
Weight gain after lung transplantation
J Heart Lung Transplant
Osteoporosis in diffuse parenchymal lung disease
Chest
Functional status and quality of life in patients surviving 10 years after lung transplantation
Am J Transplant
Pre-transplant mechanical ventilation and outcome in patients with cystic fibrosis
J Heart Lung Transplant
Living donor lobar lung transplantation: current status and future directions
Transplant Proc
Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant
Am J Transplant
Posttransplant lymphoproliferative disorder: incidence, presentation, and response to treatment in lung transplant recipients
Chest
Lung transplantation exacerbates gastroesophageal reflux disease
Chest
Improved results of lung transplantation for patients with cystic fibrosis
J Thorac Cardiovasc Surg
Transplantation
Predictive 5-year survivorship model of cystic fibrosis
Am J Epidemiol
Prediction of mortality in patients with cystic fibrosis
N Engl J Med
Outcome of patients with cystic fibrosis awaiting lung transplantation
Am J Respir Crit Care Med
Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality
Am J Respir Crit Care Med
Cited by (0)
The author has reported to the ACCP that no significant conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.